Conatus Pharmaceuticals prices upsized IPO at $11 midpoint

By Renaissance Capital,

Shutterstock photo

Conatus Pharmaceuticals, a biotech in Phase 2 trials developing treatments for chronic liver disease, raised $66 million by offering 6 million shares (20% more than the 5 million originally planned) at $11, the midpoint of the $10-$12 range. Conatus Pharmaceuticals plans to list on the NASDAQ under the symbol CNAT. Stifel and Piper Jaffray acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: CNAT

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by